Singapore markets open in 3 hours 55 minutes

CGC May 2024 11.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.7300-0.2500 (-25.51%)
As of 03:58PM EDT. Market open.
Full screen
Previous close0.9800
Open1.1200
Bid0.7300
Ask0.8100
Strike11.00
Expiry date2024-05-17
Day's range0.6500 - 1.3600
Contract rangeN/A
Volume696
Open interest1.64k
  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Canopy Growth secured $50M financing, and restructured debt with an institutional investor. High Tide appointed a new CFO, as the company eyes long-term growth. SNDL intends to move forward with Parallel and Skymint acquisitions, despites the deals facing litigation. Schwazze settled wage theft claims amidst another legal challenges. Key Takeaways; Psychedelic […]

  • PR Newswire

    Canopy Growth Announces Financing to Further Strengthen Balance Sheet Including Approximately US$50 Million of New Gross Proceeds

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), today announced that on May 2, 2024, it entered into an exchange and subscription agreement (the "Agreement") with a single institutional investor (the "Investor") pursuant to which Canopy Growth is expected to receive gross proceeds of approximately US$50 million and exchange approximately C$27.5 million of existing debt maturing in September 2025 for a new senior unsecured convertible debenture of the Compa

  • Yahoo Finance Video

    Cannabis industry: DEA reclassification is a 'critical first step'

    Cannabis stocks are experiencing a surge in Tuesday's afternoon trading session, fueled by an Associated Press report indicating that the US Drug Enforcement Administration is gearing up to reclassify marijuana as a less dangerous drug. Trulieve (TCNNF) CEO Kim Rivers joins Market Domination to provide insight into the potential implications of this news. Rivers acknowledges that the reclassification process has been "a long journey," explaining the various steps and approvals the drug has undergone before reaching this stage. However, she remains hopeful that there will be "an official announcement" from the DEA confirming its agreement with the recommendation to reschedule cannabis, placing it on the same level as Tylenol and codeine. She hails this potential move as "a critical first step for regulatory and policy changes." Rivers adds that the reclassification could facilitate safer banking operations within the cannabis industry, open new pathways for research, and lead to normalization in areas such as taxation. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith